Closely held PharmaJet has announced that its WHO prequalified Tropis ID Needle-free Injection System will be used exclusively in Pakistan’s latest polio immunization campaign to deliver vaccines to 1.8 million children starting late 2025.
The campaign will use Tropis to deliver fractional dose inactivated polio vaccine (fIPV) to children between four months and 15 years of age in Lahore, the largest city in the Pakistani province of Punjab.
Previous campaigns that vaccinated over 12 million children in Pakistan, Nigeria, and Somalia showed that Tropis is an effective and preferred solution for polio immunization that can help increase campaign coverage by over 18%. The recently published study in Vaccines4 highlighted that, when compared to the standard of care (full dose with needles), Tropis demonstrated increased coverage of the second dose of IPV (IPV2) (11.2% higher), up to 47% total immunization cost savings, and 97% healthcare worker preference. The latest use in Pakistan follows recent news of Tropis adoption for polio vaccination campaigns in Afghanistan.
In a statement, Paul LaBarre, SVP global business development at PharmaJet, commented, “We are pleased that our Tropis ID Needle-free System will continue to be used in polio eradication campaigns in Pakistan. Tropis has been shown to be very effective and affordable in campaigns and routine immunizations, protecting over 12 million children against poliovirus. In recognition of World Polio Day 2025, we remain committed to the Global Polio Eradication Initiative and look forward to continuing to support the fight against poliovirus in this region.”
